GT Biopharma (GTBP)

• Market cap: $3.7M
• 1 day: 3.67%
• 5 days: -13.08%
• 1 month: -46.19%
• 3 months: -60.90%
• 6 months: -52.12%
• Year to date: -61.56%
• 1 year: -47.69%
• 5 years: -99.27%
• 10 years: -99.27%
• Sector: Healthcare
• Industry: Biotechnology

About: GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Employees: 1

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

208% more capital invested

Capital invested by funds: $220K [Q1] → $679K (+$458K) [Q2]

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

5% more funds holding

Funds holding: 20 [Q1] → 21 (+1) [Q2]

2.11% more ownership

Funds ownership: 3.92% [Q1] → 6.03% (+2.11%) [Q2]